[Form 4] LEMAITRE VASCULAR INC Insider Trading Activity

LeMaitre Vascular director Martha Shadan reported equity-based compensation awards, not open-market trades.

Rhea-AI Filing Summary

LeMaitre Vascular director Martha Shadan reported equity-based compensation awards, not open-market trades. On March 26, 2026, she was granted several small blocks of Dividend Equivalent Rights, each tied to existing restricted stock unit and performance share unit awards granted in December 2023, 2024, and 2025.

Each dividend equivalent right is described as the economic equivalent of one share of LeMaitre Vascular common stock and vests proportionately with the underlying stock awards. All transactions are coded as awards or other acquisitions, with no reported share purchases or sales in the market.

Insider Trade Summary

Grant/Award: 3.444 shares

Grant/Award 5 txns

Insider SHADAN MARTHA

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Dividend Equivalent Rights	0.3941	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights	0.472	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights	0.6426	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights	0.7276	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights	1.2077	$0.00	$0.00

Holdings After Transaction: Dividend Equivalent Rights — 17.2834 contracts (Direct)

Footnotes (5)

1. F1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
2. F2. These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
3. F3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
4. F4. These dividend equivalent rights accrued on a performance share unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
5. F5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

Key Figures

Dividend Equivalent Rights grant 1: 0.3941 rights Dividend Equivalent Rights grant 2: 0.4720 rights Dividend Equivalent Rights grant 3: 0.6426 rights +3 more

6 metrics

Dividend Equivalent Rights grant 1 0.3941 rights Award of dividend equivalent rights on March 26, 2026

Dividend Equivalent Rights grant 2 0.4720 rights Award of dividend equivalent rights on March 26, 2026

Dividend Equivalent Rights grant 3 0.6426 rights Award of dividend equivalent rights on March 26, 2026

Dividend Equivalent Rights grant 4 0.7276 rights Award of dividend equivalent rights on March 26, 2026

Dividend Equivalent Rights grant 5 1.2077 rights Award of dividend equivalent rights on March 26, 2026

Number of acquisition transactions 5 awards All transactions coded “A” as grants/awards of derivatives

Key Terms

Dividend Equivalent Rights, restricted stock unit award, performance share unit award, economic equivalent of one share

4 terms

Dividend Equivalent Rights financial

"These dividend equivalent rights accrued on a restricted stock unit award"

Dividend equivalent rights are promises that mirror the cash payments shareholders get from a company’s profits, but they are paid to holders of certain awards (like stock options or restricted stock units) rather than to actual shares. Think of them as a paycheck top‑up that matches dividends while the award is not yet a real stock, and they matter to investors because they add to employee compensation costs and potential share dilution, affecting company profitability and per‑share value.

restricted stock unit award financial

"These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023"

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

performance share unit award financial

"These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023"

economic equivalent of one share financial

"Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did LeMaitre Vascular (LMAT) director Martha Shadan report on this Form 4?

Martha Shadan reported receiving several small grants of Dividend Equivalent Rights on March 26, 2026. These awards are equity-based compensation linked to prior restricted stock unit and performance share unit grants, rather than open-market stock purchases or sales.

What are Dividend Equivalent Rights in the LeMaitre Vascular (LMAT) filing?

Dividend Equivalent Rights are described as the economic equivalent of one share of common stock. They accrue on existing restricted stock unit and performance share unit awards and vest proportionately with those underlying awards, effectively mirroring dividends paid on actual shares.

How many Dividend Equivalent Rights did Martha Shadan acquire in this LMAT Form 4?

The Form 4 lists five separate acquisitions of Dividend Equivalent Rights: 0.3941, 0.4720, 0.6426, 0.7276 and 1.2077 rights. Each line represents a small fractional award tied to a specific prior stock-based grant dating from 2023, 2024 or 2025.

Were there any open-market stock trades by the LeMaitre Vascular director in this Form 4?

No open-market trades are reported. All transactions are coded as “A”, described as grant, award, or other acquisition of Dividend Equivalent Rights. The filing does not show any common stock purchases or sales in the market by the director on this date.

How are these Dividend Equivalent Rights related to LMAT’s RSU and PSU awards?

The footnotes state these rights accrued on restricted stock unit and performance share unit awards granted on specific December dates from 2023 to 2025. They vest proportionately with each underlying award, aligning their value with the original equity grants.

Does this LMAT Form 4 change Martha Shadan’s underlying option or share positions?

The filing shows additional Dividend Equivalent Rights credited as compensation, with total amounts following each transaction such as 4.6016 or 1.2077 rights. It does not report any option exercises, disposals, or open-market trades that would reduce existing share or derivative positions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/30/2026 - 06:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SHADAN MARTHA

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MASSACHUSETTS 01803

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(1)	03/26/2026		A		0.3941		(1)	(1)	Common Stock	0.3941	$0	4.6016	D
Dividend Equivalent Rights	(2)	03/26/2026		A		0.472		(2)	(2)	Common Stock	0.472	$0	4.3113	D
Dividend Equivalent Rights	(3)	03/26/2026		A		0.6426		(3)	(3)	Common Stock	0.6426	$0	3.5389	D
Dividend Equivalent Rights	(4)	03/26/2026		A		0.7276		(4)	(4)	Common Stock	0.7276	$0	3.6239	D
Dividend Equivalent Rights	(5)	03/26/2026		A		1.2077		(5)	(5)	Common Stock	1.2077	$0	1.2077	D

Explanation of Responses:

1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

2. These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

4. These dividend equivalent rights accrued on a performance share unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Laurie A. Churchill, Attorney-in-fact	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)